Ganciclovir

CAT: 0804-HY-13637-01Size: 100 mgDry Ice: NoHazardous: No

1 / 1

CAT#:0804-HY-13637-01Size:100 mg

Selected

24/48H Stock Items & 2 to 6 Weeks non Stock Items.

Quick Request Actions

Description

Ganciclovir (BW 759), a nucleoside analogue, is an orally active antiviral agent with activity against CMV. Ganciclovir also has activity in vitro against members of the herpes group and some other DNA viruses. Ganciclovir inhibits the in vitro replication of human herpes viruses (HSV 1 and 2, CMV) and adenovirus serotypes 1, 2, 4, 6, 8, 10, 19, 22 and 28. Ganciclovir has an IC50 of 5.2 μM for feline herpesvirus type-1 (FHV-1) and can diffuse into the brain[1][2][3].

CAS Number

82410-32-0

Product Name Alternative

BW 759; 2'-Nor-2'-deoxyguanosine

UNSPSC

12352005

Hazard Statement

H360

Target

Antibiotic; CMV; HSV; Nucleoside Antimetabolite/Analog

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage

Applications

COVID-19-anti-virus

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/ganciclovir.html

Concentration

10mM

Purity

99.89

Solubility

DMSO : 60 mg/mL (ultrasonic) |H2O : 1.67 mg/mL (ultrasonic)

Smiles

O=C1NC(N)=NC2=C1N=CN2COC(CO)CO

Molecular Formula

C9H13N5O4

Molecular Weight

255.23

Precautions

H360

References & Citations

[1]Maggs DJ, et al. In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. Am J Vet Res. 2004 Apr;65 (4) :399-403.|[2]Boujemla I, et al. Pharmacokinetics and tissue diffusion of ganciclovir in mice and rats. Antiviral Res. 2016;132:111-115.|[3]Fletcher CV, et al. Evaluation of ganciclovir for cytomegalovirus disease. DICP. 1989 Jan;23 (1) :5-12.|[4]Matthews T, et al. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis. 1988 Jul-Aug;10 Suppl 3:S490-4.|[5]Duan J, Paris W, Kibler P, Bousquet C, Liuzzi M, Cordingley MG. Dose and duration-dependence of ganciclovir treatment against murine cytomegalovirus infection in severe combined immunodeficient mice. Antiviral Res. 1998;39 (3) :189-197.|[6]Faulds D, et al. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs. 1990;39 (4) :597-638.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

HSV-1; HSV-2

Citation 01

Alternative Products

Catalog	Name
7-05256	Ganciclovir

Ganciclovir

Alternative Products

Popular Products